<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04989764</url>
  </required_header>
  <id_info>
    <org_study_id>EX-05-03-20-40</org_study_id>
    <nct_id>NCT04989764</nct_id>
  </id_info>
  <brief_title>COMPARATIVE EFFECTS OF PERIOPERATIVE AND ADJUVANT CHEMOTHERAPY ON OUTCOMES OF OPERABLE GASTRIC CANCER: EXPERIENCE FROM A CANCER CARE CENTER</brief_title>
  <official_title>COMPARATIVE EFFECTS OF PERIOPERATIVE AND ADJUVANT CHEMOTHERAPY ON OUTCOMES OF OPERABLE GASTRIC CANCER: EXPERIENCE FROM A CANCER CARE CENTER</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shaukat Khanum Memorial Cancer Hospital &amp; Research Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shaukat Khanum Memorial Cancer Hospital &amp; Research Centre</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Patients with gastric adenocarcinoma&#xD;
&#xD;
        -  Comparison: perioperative chemotherapy vs. adjuvant therapy.&#xD;
&#xD;
        -  Sample size differences between the two groups.&#xD;
&#xD;
        -  Kaplan meier survival analysis, overall survival and disease free survival&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Actual">February 2021</completion_date>
  <primary_completion_date type="Actual">December 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The overall survival</measure>
    <time_frame>from January 2015 till December 2019</time_frame>
    <description>The overall survival (OS) was defined as the length of the time from date of diagnosis till last follow-up or death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The disease-free survival</measure>
    <time_frame>from January 2015 till December 2019</time_frame>
    <description>The disease free survival (DFS) as the length of the time from date of last treatment which is either perioperative or adjuvant chemotherapy to tumor relapse or death.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">108</enrollment>
  <condition>Gastric Cancer, Outcomes, Pakistan, Adjuvant Chemotherapy, Perioperative Chemotherapy</condition>
  <arm_group>
    <arm_group_label>perioperative chemotherapy vs. adjuvant therapy in gastric ca patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>perioperative chemotherapy group vs. adjuvant chemotherapy group</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        cancer patients who had histologically proven gastric adenocarcinoma diagnosed at Shaukat&#xD;
        Khanum Memorial Cancer Hospital and Research Centre (SKMCH &amp; RC), between January 2015 and&#xD;
        December 2019&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  We included histologically proven gastric adenocarcinoma patient with operable disease&#xD;
             and the patients who completed their prescribed perioperative or adjuvant chemotherapy&#xD;
             cycles&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients were excluded if they had Tis or T1, N0 disease, inoperable disease,&#xD;
             metastatic. In addition, all those who did not undergo adequate lymphadenectomy (&lt; D2)&#xD;
             or had R1 margins following surgery were excluded&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 27, 2021</study_first_submitted>
  <study_first_submitted_qc>August 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 4, 2021</study_first_posted>
  <last_update_submitted>August 3, 2021</last_update_submitted>
  <last_update_submitted_qc>August 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

